iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting

Go back to iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting
(NASDAQ: DTIL) Delayed: 7.08 +0.27 (3.96%)
Previous Close $6.81    52 Week High
Open $6.95    52 Week Low
Day High $7.20    P/E N/A 
Day Low $6.88    EPS
Volume 402,857